Abstract:Abstract Background We evaluated the long-term effect of stereotactic body radiation therapy (SBRT) for primary small hepatocellular carcinoma (HCC) ineligible for local therapy or surgery. Methods Forty-two HCC patients with tumors ≤ 100 cc and ineligible for local ablation therapy or surgical resection were treated with SBRT: 30-39 Gy with a prescription isodose range of 70-85% (median 80%) was delivered daily in three fractions. Median tumor volume was 15.4 cc (3.0-81.8) and median follow-up duration 28.7 months (8.4-49.1). Results Complete response (CR) for the in-field lesion was initially achieved in 59.6% and partial response (PR) in 26.2% of patients. Hepatic out-of-field progression occurred in 18 patients (42.9%) and distant metastasis developed in 12 (28.6%) patients. Overall in-field CR and overall CR were achieved in 59.6% and 33.3%, respectively. Overall 1-year and 3-year survival rates were 92.9% and 58.6%, respectively. In-field progression-free survival at 1 and 3 years was 72.0% and 67.5%, respectively. Patients with smaller tumor had better in-field progression-free survival and overall survival rates (<32 cc vs. ≥32 cc, P < 0.05). No major toxicity was encountered but one patient died with extrahepatic metastasis and radiation-induced hepatic failure. Conclusions SBRT is a promising noninvasive-treatment for small HCC that is ineligible for local treatment or surgical resection.

What problem does this paper attempt to address?

The problem that this paper attempts to solve is to evaluate the long - term efficacy of stereotactic body radiation therapy (SBRT) in patients with small hepatocellular carcinoma (HCC) who are not suitable for local ablation therapy or surgical resection. Specifically, the study focuses on the application effect of SBRT in the treatment of primary small hepatocellular carcinoma patients with a tumor volume of ≤100 cc and who are unable to receive local ablation therapy or surgical resection. ### Research Background Hepatocellular carcinoma (HCC) is a common malignant disease. The current main treatment methods include surgical resection and liver transplantation, which have curative intentions for small hepatocellular carcinoma. However, most HCC patients are unable to undergo surgery due to poor liver function or the location of the tumor in the central segment. In addition, although local treatment methods such as radiofrequency ablation (RFA) and percutaneous ethanol injection (PEI) have been used to treat small hepatocellular carcinoma, the optimal treatment plan is still controversial, especially in those small hepatocellular carcinoma patients who are not suitable for radical treatment. ### Research Purpose This article aims to evaluate the long - term efficacy of SBRT in patients with small hepatocellular carcinoma who are not suitable for local treatment or surgical resection, especially focusing on its impact on tumor control and patient survival rate. ### Methods - **Patient Selection**: The study included 42 HCC patients whose tumor volume was ≤100 cc and who could not receive local ablation therapy or surgical resection due to technical difficulties, poor liver function, inaccessible location or patient refusal of surgery. - **SBRT Treatment**: SBRT treatment was carried out using the Cyberknife system, with a total dose of 30 - 39 Gy, which was divided into 3 fractions. The treatment plan took into account the size and location of the tumor, as well as the dose limitations of the surrounding normal tissues. - **Efficacy Evaluation**: The tumor response after treatment was evaluated by dynamic CT scanning, and complete response (CR), partial response (PR), stable disease (SD) and progressive disease (PD) were mainly defined according to the modified Response Evaluation Criteria in Solid Tumors (RECIST). ### Results - **Short - term Efficacy**: After the initial treatment, 59.6% of the patients achieved complete response (CR), and 26.2% of the patients achieved partial response (PR). - **Long - term Efficacy**: The overall survival rates at 1 year and 3 years were 92.9% and 58.6% respectively. The local progression - free survival rates at 1 year and 3 years were 72.0% and 67.5% respectively. - **Influence of Tumor Volume**: Patients with a smaller tumor volume (<32 cc) had better local progression - free survival rate and overall survival rate. - **Safety**: No serious toxic reactions were observed, but one patient died due to extrahepatic metastasis and radiation - induced liver failure. ### Conclusion SBRT is a promising non - invasive treatment method, which is suitable for patients with small hepatocellular carcinoma who are not suitable for local treatment or surgical resection. Especially for patients with a tumor volume of less than 32 cc, SBRT shows good efficacy and safety. Future studies need to further explore the efficacy and safety of different dose and fractionation regimens.

Long-term effect of stereotactic body radiation therapy for primary hepatocellular carcinoma ineligible for local ablation therapy or surgical resection. Stereotactic radiotherapy for liver cancer

Stereotactic Body Radiation Therapy for Small Primary or Recurrent Hepatocellular Carcinoma in 132 Chinese Patients

Stereotactic body radiation therapy for small (≤5 cm) hepatocellular carcinoma not amenable to curative treatment: Results of a single-arm, phase II clinical trial

Stereotactic Body Radiation Therapy for Small Recurrent Hepatocellular Carcinoma

Managing hepatocellular carcinoma across the stages: efficacy and outcomes of stereotactic body radiotherapy

Therapeutic outcome and related predictors of stereotactic body radiotherapy for small liver-confined HCC: a systematic review and meta-analysis of observational studies

A Multi-National, Multi-Institutional Study Of Comparing An Efficacy Of Stereotactic Body Radiation Therapy And Radiofrequency Ablation For Hepatocellular Carcinoma

Stereotactic body radiotherapy alone versus stereotactic body radiotherapy after incomplete transarterial therapy for hepatocellular carcinoma

Stereotactic body radiotherapy is an alternative to radiofrequency ablation for single HCC ≤5.0 cm

Helical IMRT-Based Stereotactic Body Radiation Therapy Using an Abdominal Compression Technique and Modified Fractionation Regimen for Small Hepatocellular Carcinoma.

The Efficacy of Stereotactic Body Radiotherapy for Patients with Hepatocellular Carcinoma

Comparison of outcomes following surgical resection, percutaneous ablation or stereotactic body radiation therapy in early‐stage, solitary and small (≤3 cm) treatment‐naïve hepatocellular carcinoma

Excellent local control and tolerance profile after stereotactic body radiotherapy of advanced hepatocellular carcinoma

Clinical comparison of stereotactic body radiotherapy and radiofrequency ablation in the treatment of liver cancer

Long-Term Survival Analysis of Stereotactic Ablative Radiotherapy Versus Liver Resection for Small Hepatocellular Carcinoma

Stereotactic Body Radiation Therapy Vs. Radiofrequency Ablation in Asian Patients with Hepatocellular Carcinoma

Stereotactic Body Radiation Therapy Versus Radiofrequency Ablation in Patients with Small Hepatocellular Carcinoma: a Systematic Review and Meta-Analysis

An Initial Report of CyberKnife Stereotactic Body Radiotherapy in Treatment of Small Hepatocellular Carcinoma:A Pilot Study

Efficacy and safety of stereotactic body radiation therapy for hepatocellular carcinoma

Stereotactic body radiation therapy (SBRT) for HCC treatment: a single institution experience

Stereotactic Body Radiotherapy As a Salvage Therapy after Incomplete Radiofrequency Ablation for Hepatocellular Carcinoma: A Retrospective Cohort Study.